Literature DB >> 22454932

Acetylation of procaine amide in man studied with a new gas chromatographic method.

E Karlsson1, L Molin, B Norlander, F Sjöqvist.   

Abstract

1 A specific gas-chromatographic method was developed for determination of N-acetylprocaine amide in plasma and urine, using 4-amino-N-(2-piperidinoethyl)benzamide as an internal standard. The investigation was performed in 50 cardiac patients who had reached steady-state plasma concentrations of procaine amide. 2 The plasma concentrations of the acetylated metabolite varied between 1.0 and 15.0 μg/ml and were thus of the same order of magnitude as those of the parent drug. Especially high plasma levels of the metabolite were seen in patients with poor kidney function. 3 The urinary excretion of the metabolite varied markedly between individuals and ranged between 6 and 52% of the administered daily dose. There was a clear tendency towards higher rates of acetylation of procaine amide in patients with short plasma half-lives of isoniazid, i.e. the phenotype rapid acetylators. Because of coexisting therapy with other drugs and impaired renal function in some patients studies are required in healthy human volunteers to ascertain whether the acetylation of procaine amide and isoniazid are mediated by the same enzyme system.

Entities:  

Year:  1974        PMID: 22454932      PMCID: PMC1402529          DOI: 10.1111/j.1365-2125.1974.tb01696.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  P-AMINO-N-(2-(SUBSTITUTED AMINO)ETHYL)BENZAMIDES. POTENTIAL ANTIFIBRILLATORY DRUGS.

Authors:  P THYRUM; A R DAY
Journal:  J Med Chem       Date:  1965-01       Impact factor: 7.446

2.  The physiological disposition and cardiac effects of procaine amide.

Authors:  L C MARK; H J KAYDEN; J M STEELE; J R COOPER; I BERLIN; E A ROVENSTINE; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1951-05       Impact factor: 4.030

Review 3.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

4.  N-acetylprocainamide: an active metabolite of procainamide.

Authors:  D E Drayer; M M Reidenberg; R W Sevy
Journal:  Proc Soc Exp Biol Med       Date:  1974-06

5.  Pharmacokinetics of procainamide.

Authors:  H S Weily; E Genton
Journal:  Arch Intern Med       Date:  1972-09

6.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

7.  Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS).

Authors:  A Hanngren; O Borgå; F Sjöqvist
Journal:  Scand J Respir Dis       Date:  1970

8.  Procainamide induction of a systemic lupus erythematosus-like syndrome. Presentation of six cases, review of the literature, and analysis and followup of reported cases.

Authors:  E L Dubois
Journal:  Medicine (Baltimore)       Date:  1969-05       Impact factor: 1.889

9.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

10.  Metabolism of procainamide in rhesus monkey and man.

Authors:  J Dreyfuss; J T Bigger; A I Cohen; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

View more
  15 in total

1.  Pharmacokinetics in man of the N-acetylated metabolite of procainamide.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1975-08

2.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

Review 5.  Effect of active drug metabolites on plasma level-response correlations.

Authors:  A J Atkinson; J M Strong
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

6.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

7.  Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.

Authors:  P du Souich; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

8.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

9.  Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.

Authors:  C Sonnhag; E Karlsson
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.